Nektar Therapeutics (NKTR) Lowered to Buy at BidaskClub

BidaskClub cut shares of Nektar Therapeutics (NASDAQ:NKTR) from a strong-buy rating to a buy rating in a research report report published on Wednesday.

A number of other research analysts have also recently issued reports on the stock. Mizuho set a $89.00 target price on shares of Nektar Therapeutics and gave the company a buy rating in a research note on Thursday, March 29th. Zacks Investment Research cut shares of Nektar Therapeutics from a hold rating to a sell rating in a research note on Tuesday, January 9th. Jefferies Group boosted their price objective on shares of Nektar Therapeutics from $2.12 to $88.00 and gave the stock a buy rating in a research report on Tuesday, January 16th. Canaccord Genuity boosted their price objective on shares of Nektar Therapeutics to $94.00 and gave the stock a buy rating in a research report on Friday, March 2nd. Finally, Cowen restated a buy rating and issued a $101.00 price objective on shares of Nektar Therapeutics in a research report on Friday, March 2nd. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $71.75.

How to Become a New Pot Stock Millionaire

NASDAQ:NKTR opened at $92.54 on Wednesday. Nektar Therapeutics has a 1 year low of $17.33 and a 1 year high of $111.36. The company has a debt-to-equity ratio of 2.79, a current ratio of 5.82 and a quick ratio of 5.63. The company has a market capitalization of $15,080.08, a PE ratio of -168.25 and a beta of 1.74.



Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.14. Nektar Therapeutics had a negative net margin of 31.42% and a negative return on equity of 156.85%. The company had revenue of $95.47 million during the quarter, compared to analysts’ expectations of $36.96 million. During the same quarter in the previous year, the company posted ($0.28) earnings per share. Nektar Therapeutics’s quarterly revenue was up 154.9% compared to the same quarter last year. sell-side analysts anticipate that Nektar Therapeutics will post -1.43 EPS for the current year.

In related news, SVP Stephen K. Doberstein sold 2,426 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $82.94, for a total value of $201,212.44. Following the completion of the transaction, the senior vice president now owns 67,394 shares in the company, valued at approximately $5,589,658.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Jillian B. Thomsen sold 2,545 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $82.94, for a total transaction of $211,082.30. The disclosure for this sale can be found here. Insiders sold a total of 588,473 shares of company stock valued at $54,878,447 in the last 90 days. 6.10% of the stock is currently owned by corporate insiders.

Several institutional investors have recently modified their holdings of the business. Crossmark Global Holdings Inc. raised its position in shares of Nektar Therapeutics by 2.8% during the 4th quarter. Crossmark Global Holdings Inc. now owns 30,168 shares of the biopharmaceutical company’s stock valued at $1,802,000 after acquiring an additional 829 shares during the last quarter. Amalgamated Bank raised its position in shares of Nektar Therapeutics by 6.3% during the 4th quarter. Amalgamated Bank now owns 21,775 shares of the biopharmaceutical company’s stock valued at $1,300,000 after acquiring an additional 1,298 shares during the last quarter. Flinton Capital Management LLC raised its position in shares of Nektar Therapeutics by 20.6% during the 4th quarter. Flinton Capital Management LLC now owns 10,976 shares of the biopharmaceutical company’s stock valued at $655,000 after acquiring an additional 1,872 shares during the last quarter. Thrivent Financial For Lutherans raised its position in shares of Nektar Therapeutics by 2.0% during the 4th quarter. Thrivent Financial For Lutherans now owns 97,655 shares of the biopharmaceutical company’s stock valued at $5,832,000 after acquiring an additional 1,925 shares during the last quarter. Finally, BB&T Investment Services Inc. bought a new stake in shares of Nektar Therapeutics during the 4th quarter valued at $119,000. Institutional investors own 96.32% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Nektar Therapeutics (NKTR) Lowered to Buy at BidaskClub” was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://stocknewstimes.com/2018/04/19/nektar-therapeutics-nktr-lowered-to-buy-at-bidaskclub.html.

About Nektar Therapeutics

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain based on its PEGylation and polymer conjugate technology platforms in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply